PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
- None.
- None.
The reported preliminary revenue figures for PROCEPT BioRobotics Corporation signify a substantial year-over-year growth for Q4 and the fiscal year. With an 81% to 82% increase in annual revenue, the company demonstrates a robust financial performance, likely fueled by the adoption of its Aquablation Therapy and an expanded sales team. The impressive growth in U.S. system sales, particularly the sale of 44 robots at a high average price point, indicates a strong market demand for the company's surgical robotics solutions.
Investors should note the high utilization rate of sold handpieces, which suggests recurring revenue potential from consumables and services. The service revenue of approximately $2.1 million, although a small fraction of the total, is a stable income stream that complements the more variable system sales. The international revenue of $3.3 million, while modest in comparison to U.S. sales, hints at the company's potential for global expansion.
However, stakeholders should remain cautious until the audited results are published, as adjustments could modify the preliminary figures. It is also important to monitor the company's operating expenses and net income to fully assess its profitability and the sustainability of its growth trajectory.
The data reflects a growing acceptance of PROCEPT's surgical robotics in urology, a field that has been increasingly embracing technological advancements. The company's strategic positioning, with the largest capital sales team in its history, suggests a targeted effort to capture market share. The rapid adoption within urology practices is a testament to the efficacy and value proposition of Aquablation Therapy.
The high average selling price of the systems indicates a premium product offering, which, coupled with the monthly utilization rates, suggests that PROCEPT's solutions are gaining traction not just in sales but also in practical use. This is pivotal for long-term growth as it points to a sustainable customer base that will require ongoing support, training and upgrades.
Furthermore, the strong surgeon interest and real-world clinical outcomes could signal future growth opportunities. However, it is essential to analyze the competitive landscape and potential market saturation points. The company's ability to innovate and differentiate its offerings will be crucial in maintaining its growth momentum in the face of competition.
The reported figures underscore a significant achievement in the medical device sector, particularly within the niche of surgical robotics for urology. PROCEPT BioRobotics Corporation's growth is indicative of successful market penetration and the clinical acceptance of its Aquablation Therapy. This therapy represents a novel approach in treating conditions such as benign prostatic hyperplasia (BPH) and its adoption could reflect a shift in standard care practices.
From an industry perspective, the sale of 44 robotic systems in a single quarter is remarkable and showcases the potential scalability of such technologies. The service revenue component aligns with industry trends towards service-based models that provide continuous revenue streams post-device sale.
As the company prepares for future growth, it will be important to monitor how it manages production scaling, regulatory challenges and reimbursement landscapes, which are critical factors for success in the medical device industry. The balance between investing in growth and managing operational costs will be key to maintaining profitability in a sector known for high research and development expenses.
SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023.
Preliminary, Unaudited Revenue Highlights:
- Total revenue for the fourth quarter of 2023 is expected to be in the range of
$43.3 million to$43.6 million , compared to$23.8 million in the prior year period.- Total U.S. revenue of approximately
$40.0 million to$40.3 million for the fourth quarter of 2023 - Total U.S. Handpieces sold of approximately 6,400 resulting in monthly utilization of approximately 7.3 for the fourth quarter of 2023
- U.S. system sales of 44 robots at an average selling price of approximately
$375 thousand per system - Total U.S. service revenue of approximately
$2.1 million for the fourth quarter of 2023 - Total international revenue of approximately
$3.3 million for the fourth quarter of 2023
- Total U.S. revenue of approximately
- Fiscal year 2023 revenue is expected to be approximately
$135.9 million to$136.2 million , representing growth of approximately81% to82% compared to the prior year period.
“We are very pleased to close out 2023 with another quarter of excellent results, driven by an acceleration in monthly utilization and strong U.S. system sales,” said Reza Zadno, Chief Executive Officer. “As we enter 2024, we are well positioned to continue to deliver outsized revenue growth driven by outstanding real-world clinical outcomes of Aquablation Therapy, the largest and most tenured capital sales team in the company’s history, and strong surgeon interest leading to rapid adoption within urology practices.”
The Company plans to report financial results for the fourth quarter and fiscal year 2023 after market close on Tuesday, February 27, 2024. The Company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The preliminary results included in this press release are unaudited and remain subject to adjustment.
Investors interested in listening to the conference call may do so by following one of the below links:
- Webcast link for interested listeners:
- Dial-in registration for sell-side research analysts:
Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com
An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Forward‐Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected preliminary financial performance for full year 2023, statements regarding the potential utilities, values, benefits and advantages of Aquablation® therapy performed using PROCEPT BioRobotics’ products, including AquaBeam® Robotic System, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margin, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 28, 2023. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
FAQ
What did PROCEPT BioRobotics Corporation (PRCT) report for the quarter and fiscal year ended December 31, 2023?
What is the expected total revenue for the fourth quarter of 2023?
How does the total revenue for the fourth quarter of 2023 compare to the prior year period?
What is the expected fiscal year 2023 revenue for PROCEPT BioRobotics Corporation (PRCT)?
When will the Company report financial results for the fourth quarter and fiscal year 2023?
